Related Experiment Videos
How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis
Kévin Bigaut1, Mikaël Cohen2, Françoise Durand-Dubief3
1Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Background:
Today, there are no recommendations on switching disease-modifying treatments (DMTs) in multiple sclerosis (MS).
Objectives:
To establish guidelines on switching DMTs MS.
Methods:
A Steering Committee composed of seven MS experts from the French Group for Recommendations in Multiple Sclerosis (France4MS) defined 15 proposals. These proposals were then submitted to a Rating Group, composed of 48 French MS experts, for evaluation. The proposals were classified as 'appropriate', 'inappropriate' or 'uncertain'.
Results:
Switching from a first-line therapy to another first-line therapy or a second-line therapy could be done without a washout period. Switching from a second-line therapy to a first-line therapy could be done without a washout period with fingolimod or natalizumab, after 3 months with ocrelizumab or mitoxantrone, and, if disease activity occurs with alemtuzumab or cladribine. The switch from a second-line therapy to another second-line therapy could be done after a washout period of 1 month with fingolimod or natalizumab, after 3 months with ocrelizumab, after 6 months with mitoxantrone, and, if disease activity occurs, with alemtuzumab or cladribine.
Conclusion:
This expert consensus approach provides physicians with some guidelines on optimizing the benefit/risk ratio when switching DMTs in patients with MS.